Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s Menactra Use Expanded To Children

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.

You may also be interested in...



Phase III Menveo Beats Menactra In Teen Meningitis

Novartis will submit vaccine for U.S. and overseas approval later this year.

Phase III Menveo Beats Menactra In Teen Meningitis

Novartis will submit vaccine for U.S. and overseas approval later this year.

Generic Ambien Assaults Sanofi’s Top Line, But Lantus Growth Offsets Drop In Sales

Net sales fell 6 percent in the fourth quarter, but plummeting Ambien IR revenues are counteracted by 30 percent rise in insulin brand Lantus.

Related Content

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel